anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides an anti-tumor traditional Chinese medicine preparation and a preparation method thereof. The anti-tumor traditional Chinese medicine preparation comprises the following components: 3-20g ganoderma lucidum, 3-15g cordyceps sinensis and 1-10 eggs. The preparation method comprises the steps that the ganoderma lucidum and the cordyceps sinensis are processed into fine powder respectively; the eggs are broken, mixed uniformly, dried and then processed into fine powder; the three types of fine powder are mixed; auxiliary materials is added to the fine powder; particles are formed; and then the particles are packaged into bags. The anti-tumor traditional Chinese medicine preparation is a pure traditional Chinese medicine preparation, few in raw materials, low in cost and reasonable in prescription, tonic, non-greasy, mild in drug property, safe and effective, is based on the idea of 'keeping healthy atmosphere and keeping away pathogenic factors'. can strengthen the body resistance, and can effectively improve immunity. Through clinical verification, if the anti-tumor traditional Chinese medicine preparation is taken for a long time, various tumors can be prevented from spreading to different extents, the immunity can be improved obviously, toxic and side effects of chemoradiotherapy drugs can be reduced, and effects after chemoradiotherapy can be improved.
Production of a product with predominantly sterol character (a) from estrone by dissolving pure estrone in a boiling solvent (pref. EtOH), cooling, adding a peroxide (pref. H2O2, pref. together with Ac2O), stirring the mixture at 40-60 deg.C and adjusting to pH ca 5-5.5 with a base, and extracting the product, together with other components, with a solvent (pref. C6H6); (b) from natural products such as lemon juice by treating with a strong base to pH 11-11.5; and subjecting the basic soln. to extraction with petroleum ether (b.p. 40-60 deg.C); (c) from a flavonoid complex by mixing this with MeOH, centrifuging the insoluble residue and again washing this with MeOH to give an MeOH extract; or (d) from testosterone by an enzymatic method by triturating and homogenising placental tissue (freed from vessels and connective tissue) with a nearly neutral phosphate buffer; repeatedly freezing and thawing the mixture; centrifuging and homogenising the product; separating off the lipids; collecting and lyophilising the clear supernatant liquid; subjecting the lyophilisate to electrophoresis on a block of polyvinyl acetate or chloride with veronal-sodium acetate buffer at slightly basic pH; removing the cathode-migrating fraction and subjecting it to an induction in the presence of testosterone; chromatographically separating the components; washing the components with an alcohol/acetone mixture and separating off the supernatant; and recovering the solid sterol residue (after precipitation in EtOAc). The products may be further purified.
Three different brand scanbodies (Straumann, Medentika, 3Shape) that applied in same participant group with randomization are used in this clinical study. These three different scan bodies are digitized using an intraoral scanner. Three different temporary restorations are designed in the CAD program and three different bridges are produced with the milling technique using the temporary restoration block. Clinical and analytic evaluations were perform and primarly, seconderly outcomes were achieved.
In clinical practice, manual muscle testing (MMT) and Modified Ashworth scale (MAS) grading systems are often used to assess muscle tension and tension. Although these methods are considered feasible, because these methods are mainly classified based on the subjective perception of the evaluator, the reliability and accuracy of the evaluation results are often questioned. Therefore, we should seek a way to objectively evaluate muscle tension with biomechanical properties and quantitative data to solve these deviations. MyotonPRO (Myoton AS, Tallinn, Estonia) is a tester that uses biomechanical principles to collect muscle tension status. This handheld muscle tension tester uses mechanical pressure and reaction force feedback to calculate through biomechanical conversion. The tone, stiffness and elasticity of the muscle are expressed as quantitative data. There have been many use reports showing that the muscle tone meter has the feasibility of quantifying muscle tone.

The erector spinae is one of the most important back muscles of the human body. After contraction, the entire spine can be erected, allowing the upper body to stand upright. When the posture changes, such as: sitting posture, hunchback, bending over, erector spinae will be stretched or continuously contracted due to different postures, resulting in changes in muscle characteristics. Therefore, if the erector spinae is used improperly for long-term poor posture, the erector spinae is easily damaged due to heavy burden, which can easily cause back pain. Myofascial release (myofascial release) is a soft tissue massage method that loosens the fascia with hands. By changing the mechanical properties of the muscles, it can loosen over-tension or tense muscles. It is the most commonly used by physical therapists to loosen muscles. One of the operation techniques. However, there is no literature to quantify the effect of myofascial mobilization. The purpose of this experiment is to evaluate whether MyotonPRO can quantify the changes in the muscle characteristics of the erector spinae in different postures and after myofascial relaxation, and to test the validity of the muscle tone tester.
PURPOSE: Inflammatory factors play an important role in the onset and progression of colorectal cancer (CRC). This study aimed to develop and validate a novel scoring system that utilizes specific inflammatory factor indicators to predict intestinal obstruction in CRC patients.
METHODS: This study conducted a retrospective analysis of 1,470 CRC patients who underwent surgical resection between January 2013 and July 2018. These patients were randomly allocated to the training group (n = 1060) and the validation group (n = 410). Univariate and multivariate logistic regression analyses were performed to identify independent predictive factors for intestinal obstruction. The CRC peculiar inflammation score (CPIS), comprising lymphocyte-to-monocyte ratio (LMR), prognostic nutrition index (PNI), and alanine transaminase-to-lymphocyte ratio index (ALRI) scores, was significantly associated with the occurrence of intestinal obstruction. A nomogram combining CPIS with other clinical features was developed to predict this occurrence. Model accuracy was assessed by determining the area under the receiver operating characteristic (ROC) curve (AUC).
RESULTS: The CPIS generated by multi-factor logistic regression was as follows: - 1.576 × LMR - 0.067 × PNI + 0.018 × ALRI. Using CPIS cutoff values of 50% (- 7.188) and 85% (- 6.144), three predictive groups were established. Patients with a high CPIS had a significantly higher risk of intestinal obstruction than those with a low CPIS (odds ratio [OR]: 10.0, confidence interval [CI]: 5.85-17.08, P < 0.001). The predictive nomogram demonstrated good calibration and discrimination abilities. The AUC of the ROC curve for the obstruction nomogram was 0.813 (95% CI: 0.777-0.850) in the training set and 0.806 (95% CI: 0.752-0.860) in the validation set. The calibration curve exhibited neither bias nor high credibility. Decision curve analysis indicated the utility of this predictive model.
CONCLUSION: CRC-associated intestinal obstruction is closely linked to inflammatory markers in patients. CPIS is a CRC-specific inflammatory predictive score based on a combination of inflammatory-related indicators. A high CPIS serves as a strong indicator of intestinal obstruction. Its integration with other clinical factors and preoperative inflammatory-specific indicators significantly enhances the diagnosis and treatment of CRC patients with intestinal obstruction.
Patients receive vosaroxin IV over 10 minutes on days 1 and 4 and azacitidine SC or IV over 15 minutes on days 1-7. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
The trial product is MagicTouch sirolimus drug coated balloon (Concept Medical). Sirolimus will be transferred from the balloon to the vessel wall by inflating the sirolimus coated balloons at 2 minutes at rated burst pressure (typically 12 to 14ATM). All the lesions within the dialysis circuit with sirolimus coated balloon.
A composition (A) comprising murine embryonal stem cells (ESC) intended for therapeutic use in primates, is new. A composition (A) comprising murine embryonal stem cells (ESC) intended for therapeutic use in primates. The composition is obtained by in vitro maintaining of the undifferentiated cell of the mouse in a culture medium with a compound, in vitro culturing of the undifferentiated cells without the compound and purifying the cells by negative selection of an antibody/ligand specifically directed against a specific marker of the undifferentiated cells or by positive selection using an antibody/ligand specifically directed against a specific marker of a phenotype of the initiated cells. The cells are engaged in the differentiation way in neurons, hematopoietic cells, osteogenic cells, chondrocytes, spinal cord, oligodendrocytes or precursors of the cell line. ACTIVITY : Cardiant; Hepatotropic; Cytostatic; Antiinflammatory; Antidiabetic; Neuroprotective; Osteopathic; Antiarthritic; Nootropic; Antiparkinsonian; Anticonvulsant; Vulnerary; Dermatological. No biological data given. MECHANISM OF ACTION : Cell and tissue replacement.
Picoprep is a low-volume bowel preparation used to optimize visualization of the colonic mucosa during colonoscopy. Patients referred for a colonoscopy will be scheduled for an intake. During this intake patients receive education about Picoprep and will be asked about their health condition (medical history, medication use). Standard a face-to-face education is given by an intake nurse or doctor. The producers of Picoprep, Ferring BV designed an app including a drinking schedule adapted to the timing of the coloscopy, aiming a lag time between intake of the last Picoprep dose and the scopy of 2-4 hours. We hypothesize that the Boston Bowel Preparation Scale and patient satisfaction will be higher in patients receiving standard education plus using the bowel preparation app versus patients receiving single standard education.
Patients in the experimental group will receive the brief, individual, manualized CALM intervention, a semi-structured psychotherapy designed for patients with advanced cancer. CALM was developed based on empirical results, clinical observation and the theoretical foundations of supportive-expressive and existential approaches, as well psychodynamic and attachment theories. The sessions are delivered bimonthly over a period of 6 months. Sessions are reviewed to ensure treatment fidelity.
PURPOSE OF REVIEW: This review focuses on the use of colchicine to target inflammation to prevent cardiovascular events among those at-risk for or with established coronary artery disease.
RECENT FINDINGS: Colchicine is an anti-inflammatory drug that reduces cardiovascular events through its effect on the IL-1β/IL-6/CRP pathway, which promotes the progression and rupture of atherosclerotic plaques. Clinical trials have demonstrated that colchicine reduces cardiovascular events by 31% among those with chronic coronary disease, and by 23% among those with recent myocardial infarction. Its ability to dampen inflammation during an acute injury may broaden its scope of use in patients at risk for cardiovascular events after major non-cardiac surgery. Colchicine is an effective anti-inflammatory therapy in the prevention of acute coronary syndrome. Ongoing studies aim to assess when, and in whom, colchicine is most effective to prevent cardiovascular events in patients at-risk for or with established coronary artery disease.
Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 250C. of at least about 10 cps or about 100 cps at a shear rate of 0. I/second. In a preferred embodiment, the viscosity at 25'C. is in the range of from about 80,000 cps to about 300,000 cps. H:\tzm\Interwoven\NRPortbl\DCC\TZM\6121494 1.DOC - 24/3/14
Traffic-related air pollution (TRAP) poses a significant public health risk that is associated with adverse birth outcomes. Large roadway infrastructure projects present a natural experiment to examine how resulting congestion change is associated with adverse birth outcomes for nearby populations. This study is designed to examine the influence of living close to a roadway before, during, and after a construction project using a difference-in-differences design. We integrated data on all large roadway construction projects (defined as widening of existing roads, building new roads, improving bridges, installing intelligent transportation systems, improving intersections, and installing or upgrading traffic signals) in Texas from 2007 to 2016 with Vital Statistic data for all births with residential addresses within 1 km of construction projects. Our outcomes included term low birth weight, term birth weight, preterm birth, and very preterm birth. Using a difference-in-differences design, we included births within 3 years of construction start and 2 years of construction end. In our main model, the exposed group is limited to pregnant individuals residing within 300 m of a construction project, and the control group includes those living within 300-1000 m from a project. We used regression models to estimate the influence of construction on infant health. We included 1,360 large roadway construction projects linked to 408,979 births. During construction, we found that the odds of term low birth weight increased by 19% (95% CI: 1.05, 1.36). However, we saw little evidence of an association for other birth outcomes. Contrary to our hypothesis of decreased TRAP after construction ends, we did not observe consistent improvements post-construction for pregnant individuals living within 300 m. Continued consideration of the influence of traffic congestion programs on birth outcomes is necessary to inform future policy decisions.
FIELD: medicine. SUBSTANCE: preparation is designed as a tablet and consists of microparticles of laminaria, mainly, the size of particles is below 100 mcm, and lactose at 60-90 : 40-10 ratio. The preparation stabilizes membranous processes, protects body cells against artificial aging, it is of antimutagenic and radioprotective action. It is efficient to protect against radiation and its impact effects upon a body, normalize immune system, remove stresses, at complex therapy of infectious-allergic, viral and other diseases, obesity, thrombophlebitis, in treating goiter, and preventing the development of atherosclerosis. EFFECT: higher efficiency of protection. 3 cl, 8 ex, 6 tbl
DFF332 Single Agent in patients with ccRCC (age 18 years old and above). This arm will not open.
The invention discloses a FZD7 mouse-derived monoclonal antibody, a preparation method and application thereof. The FZD7 murine monoclonal antibody comprises a heavy chain variable region comprising the amino acid sequence shown in SEQ ID No. 1 or an amino acid sequence having at least 99% sequence identity to the sequence shown in SEQ ID No. 1 and a light chain variable region comprising the amino acid sequence shown in SEQ ID No. 2 or an amino acid sequence having at least 99% sequence identity to the sequence shown in SEQ ID No. 2. The FZD7 mouse-derived monoclonal antibody obtained by the invention can be combined with FZD7 protein in vitro and in vivo, and has clinical development value.
Cleansers for the skin comprise essentially: one or more reaction products of sulphuric or phosphoric acid with alcohols having more than 10 carbon atoms, or salts thereof, e.g. the sodium, potassium, or triethanolamine salts; floridin and/or bentonite and/or colloidal kaolin which have a buffering action; and a binder consisting of tragacanth, starch, dextrin, or a synthetic thickener.  Suitably 8 lb. of the sodium salt of cetylic alcohol sulphonic acid, 67 lb. of colloidal kaolin, and 25 lb. of 3 per cent tragacanth solution, are mixed, kneaded, and moulded. Cork meal or the like may be added to make the tablets float. Specification 401,413 is referred to.  The invention as described in the Specification as open to inspection under Sect. 91 is for a non-alkaline non-saponaceous detergent for the body containing one or more products of reaction of a polybasic inorganic acid with alcohols containing more than 10 carbon atoms, or a salt thereof, and one or more mineral substances in colloidal condition.  Bole is one of the minerals specified.
Depending on their preference, each participant wearing personalized headphones was played instrumental music in the pre-menstruation period for 30 minutes. The procedure was performed once on the first day and once on the second day of menstruation.
BACKGROUND: Management of intrahepatic cholangiocarcinoma (IHC) has advanced in recent decades, including randomized trial evidence supporting systemic therapy in the palliative and adjuvant setting. Mounting observational evidence suggests resection of IHC with multifocal disease (IHC-MF) or lymph node metastasis (IHC-LNM) should be limited. It is unknown how real-world practice has evolved in light of research advances. This study characterizes trends in management and outcomes of IHC without distant metastasis.
METHODS: We queried the National Cancer Database (NCDB) for patients treated for IHC without distant metastasis (M0) and identified subgroups with lymph node (cN1) or multifocal hepatic involvement (cT2b). Two-sided Cochran-Armitage tests evaluated trends in initial treating modality and perioperative chemotherapy. Logistic regression evaluated associations with choice of initial treating modality. Overall survival (OS) was evaluated by using Kaplan-Meier methods.
RESULTS: Between 2004 and 2020, 11,368 patients were treated for IHC without extrahepatic metastasis. Forty-three percent underwent resection. Initial management shifted from resection towards radiation or systemic therapy in IHC-MF and IHC-LNM. Use of perioperative chemotherapy increased from 39% pre-2010 to 70% in 2018-2020 (p < 0.001), most often delivered postoperatively. Across the entire cohort, median OS improved from 16 (95% confidence interval [CI] 15-18) to 27 months (95% CI 26-29). More modest improvements were observed in IHC-MF and IHC-LNM.
CONCLUSIONS: Use of perioperative chemotherapy has been widely adopted, predating randomized trial evidence in the adjuvant setting. Initial management of IHC-MF and IHC-LNM has shifted from resection to systemic and/or radiation therapy. While OS has improved overall, outcomes of IHC-MF and IHC-LNM remain poor, warranting further investigation.
<P>PROBLEM TO BE SOLVED: To provide a simple method for enhancing affinity of an optionally weakly binding targeted molecule so as to heighten usefulness for a diagnosis and/or therapeutic object.  <P>SOLUTION: An organized mobile multicomponent conjugate (OMMC) to enhance binding of compounds weakly binding to a target and a method of using the same, are provided. A lamellar structure containing at least two binding compounds is assembled under the conditions in which the binding compounds self-regulate in or on the laminar structure, forming a cooperative ensemble capable of binding with enhanced affinity to a complementary affinity site on a target. Each binding compound is bound to the lamellar surface and may be connected by a linker. The OMMC may contain an effector molecule such as a diagnostic or therapeutic agent for administration to a patient to be diagnosed or treated by using the effector molecule.  <P>COPYRIGHT: (C)2010,JPO&INPIT
NEW MATERIAL:The benzoic acid derivative of formula I (X is halogen; Y is H or OH) or its salt. EXAMPLE:4-[3-( 4-Acetyl-3-hydroxy-2-n-propylphenoxy )-2-hydroxypropoxy]-chlorobenzoic acid. USE:It has antagonistic activity against the slow reacting substance of anaphylaxis (SRS-A) which is a chemical transmission substance causing the contraction of the bronchial smooth muscle, etc., and is useful as a remedy for asthma, hay fever, chronic bronchitis, allergic diseases of the eye, etc. PROCESS:The compound of formula I can be prepared by hydrolyzing the compound of formula II (Z is nitrile, carbamoyl or alkoxycarbonyl) with an acid or alkali. The reaction is preferably carried out generally in an organic solvent such as methanol, aetic acid, etc. at a temperature between about 50 deg.C and about the boiling point of the solvent.
The safety and efficacy of dabrafenib alone or administered with MEKINIST were evaluated in a multi-center, three-cohort, non-randomized, activity-estimating, open-label trial (Study BRF113928; NCT01336634). Key eligibility criteria were locally confirmed BRAF V600E mutation-positive metastatic NSCLC, no prior exposure to BRAF or MEK inhibitor, and absence of EGFR mutation or ALK rearrangement (unless patients had progression on prior tyrosine kinase inhibitor therapy). Patients enrolled in Cohorts A and B were required to have received at least one previous platinum-based chemotherapy regimen with demonstrated disease progression but no more than three prior systemic regimens. Patients in Cohort C could not have received prior systemic therapy for metastatic disease. Patients in Cohort A received dabrafenib 150 mg twice daily. Patients in Cohorts B and C received MEKINIST 2 mg once daily and dabrafenib 150 mg twice daily. The major efficacy outcome was ORR per RECIST v1.1 as assessed by independent review committee (IRC) and duration of response.

There were a total of 171 patients enrolled which included 78 patients enrolled in Cohort A, 57 patients enrolled in Cohort B, and 36 patients enrolled in Cohort C. The characteristics of the population were: a median age of 66 years; 48% male; 81% White, 14% Asian, 3% Black, and 2% Hispanic; 60% former smokers, 32% never smokers, and 8% current smokers; 27% had ECOG performance status (PS) of 0, 63% had ECOG PS of 1, and 11% had ECOG PS of 2; 99% had metastatic disease of which 6% had brain metastasis at baseline and 14% had liver metastasis at baseline; 11% had systemic anti-cancer therapy in the adjuvant setting, 58% of the 135 previously treated patients had only one line of prior systemic therapy for metastatic disease; 98% had non-squamous histology.

Efficacy results are summarized in Table 23.

In a subgroup analysis of patients with retrospectively centrally confirmed BRAF V600E mutation-positive NSCLC with the Oncomine™ Dx Target Test, the ORR results were similar to those presented in Table 16.
530,548. Vitamin D. STEVENS, A. H. (General Mills Inc.). June 27, 1939, No. 18681. [Class 2 (iiij] Vitamin D is concentrated from either naturally occurring or synthetic vitamin D concentrates by dissolving the vitamin D- containing material in an organic solvent, passing the solution through tricalcium phosphate, preferably activated, washing the phosphate with an organic solvent to dissolve the adsorbed vitamin D and separating the vitamin D from the solvent by distilling off the solvent. The tricalcium phosphate is preferably activated by heating for about 2 hours at 120‹-130‹C. Solvents mentioned are petroleum ether, hexane, benzene or ether. The solution of vitamin D-containing material can be passed through a column of tricalcium phosphate or agitated with the solid. In the example a solution of activated ergosterol in petroleum ether is filtered through a column of tricalcium phosphate, the vitamin D adsorbed on the tricalcium phosphate is dissolved in diethyl ether and the solvent is then distilled off.